Clinical Study on Xuesaitong Soft Capsule for Patients with Unstable Angina Pectoris: a Randomized Controlled Trial

Phase 4

• Conditions: unstable angina pectoris

• Registration Number: ITMCTR2000003228
• Lead Sponsor: Xiyuan Hospital of China Academy of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Aged 40-75 years, male or female;
2. Patients who meet the diagnosis of unstable angina pectoris and undergo coronary intervention.

Exclusion Criteria

Those who meet any of the following are excluded:
1. Those with hypertension who still have high blood pressure after treatment with antihypertensive drugs (systolic blood pressure >= 180mmHg, diastolic blood pressure >= 100mmHg);
2. Severe arrhythmia (atrial fibrillation with rapid ventricular response, atrial flutter, paroxysmal ventricular tachycardia, etc.);
3. Pulmonary heart disease, rheumatic heart disease, myocarditis, cardiomyopathy, aortic dissection, pulmonary embolism;
4. Gastrointestinal ulcer;
5. History of infection, fever, trauma, burns, and surgery within the past month;
6. Acute myocardial infarction or acute stroke in the past month;
7. Active rheumatoid immune disease;
8. Active tuberculosis;
9. Those whose serum alanine aminotransferase or serum creatinine is > 2 times the upper limit of the normal reference value;
10. People with severe hematological diseases;
11. Malignant tumors;
12. Pregnant women, lactating women, or women of childbearing age with childbearing requirements;
13. People with mental illness or cognitive impairment;
14. Those who are allergic to the test drug;
15. Participants in other clinical trials in the last 1 month;
16. Those who refuse to sign the informed consent.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hs-CRP;

Secondary Outcome Measures

Name	Time	Method
interleukin-6;endothelin-1;platelet aggregation rate;von Willebrand Factor;Routine blood test;liver function;tumor necrosis factor-a;Urine routine;stool routine;Nitric Oxide;